Health

Health and lifestyle features.

Selon de nouvelles données divulguées à l’occasion de la Journée mondiale contre le sida, moins d’enfants naissent avec le VIH ; mais UNITAID met en garde de ne pas négliger ceux qui en sont déjà atteints

À l’occasion de la Journée mondiale contre le sida, UNITAID se félicite de constater que le nombre d’enfants nouvellement infectés par le VIH continue de baisser, mais prie instamment la communauté internationale d’intensifier les efforts pour ceux qui vivent déjà avec cette maladie.

一日一粒タイプの良質オーストラリア産プロポリスカプセルを只今販売中!

今週から、オーストラリア産蜜蜂サプリメントのスペシャリストNatural Life™(ナチュラルライフ)は、待望の一日一粒タイプのプロポリスカプセルを発売します。

Mindfulness? – There’s an App for that

Scandinavia’s best selling mindfulness application is finally available in the UK!

UNITAID investments to bring innovative HIV diagnostic technologies to world's poorest

UNITAID today announced the largest investment yet in “point-of-care” and decentralized HIV diagnostic products to bring life-saving technologies out of the drug development pipeline and into remote communities most affected by the epidemic. 

Press Conference: UNITAID, CHAI-UNICEF and MSF to Bring Cutting-Edge HIV Diagnostic Technologies to World's Poorest

A new set of investments by global health initiative UNITAID will revolutionize the HIV/AIDS response in low-income countries by bringing new and advanced HIV diagnostics to patients in the most remote communities.

Kenta Biotech registriert ersten Patienten für den „First-in-human“-Versuch mit dem vielversprechenden mono-klonalen Antikörper KBSA301

Kenta Biotech hat heute einen wichtigen Schritt für eine effektivere Behandlung von Spitalinfektionen angekündigt: Der erste Patient wurde für die klinische Phase I/II-Studie mit KBSA301 registriert. KBSA301 ist ein rein humaner Antikörper zur Behandlung schwerer Lungenentzündungen, die durch Staphylococcus aureus-Bakterien (S. aureus) verursacht werden.

Kenta Biotech includes first patient in its first-in-human trial of promising monoclonal antibody KBSA301

Kenta Biotech today announced an important step towards a more efficient treatment of hospital infections: The first patient was enrolled in the phase I/II clinical trial with KBSA301, a fully human antibody for the treatment of severe pneumonia caused by Staphylococcus aureus (S. aureus).

UNITAID approves US$ 30 million for innovative project to roll out ground-breaking tuberculoses test at reduced cost

The executive board of UNITAID today approved funding of US$ 30 million to scale up access to a new diagnostic test for tuberculosis, Xpert MTB/RIF, and reduce the cost of its use.

Kenta Biotech vollzieht mit Umzug in den Bio-Technopark Zürich-Schlieren wichtigen strategischen Schritt

Kenta Biotech verlegt ihren Firmensitz von Bern in den Bio-Technopark in Zürich-Schlieren, dem Silicon Valley der Schweizer Biotechnologie.

Kenta Biotech makes strategic move by relocating to Bio-Technopark in Zurich-Schlieren

Kenta Biotech announced today that it is relocating from Bern to Bio-Technopark in Zurich-Schlieren, the Silicon Valley of Swiss Biotechnology.

Pages

Subscribe to RSS - Health